BUSINESS● LOWSep 24 · Sep 24, 2026, 12:03 PM
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy
Seeking Alpha Tech · global
Acadia Pharmaceuticals' stock declined following a setback in a mid-stage clinical trial for its Alzheimer's psychosis therapy. This impacts the company's research and financial standing.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS1h agoWilliam “Bill” Bengen, investment expert: 'Inflation is the greatest enemy of retirees'ClarínBUSINESS1h agoWhy 17 is not the magic number in industrial policyFinancial Times